Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     

THERMO FISHER SCIENTIFIC

(TMO)
  Report
Delayed Nyse  -  04:00 2022-12-07 pm EST
558.14 USD   +1.38%
09:54aThermo Fisher Scientific Launches TrueMark Infectious Disease Research Panels
AQ
08:16aRBC Initiates Thermo Fisher Scientific at Outperform With $660 Price Target, Cites 'Advantageous Position'
MT
12/06Thermo Fisher Scientific Raises Greenhouse Gas Emissions Reduction Target on Path to Net-zero Emissions
BU
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Thermo Fisher Scientific Certifies Applies Biosystems QuantStudio 7 Pro Dx Real-Time PCR System to Meet IVDR Requirements

09/12/2022 | 02:30am EST

Thermo Fisher Scientific has certified the Applied Biosystems QuantStudio 7 Pro Dx Real-Time PCR System to meet new In Vitro Medical Devices Regulation (IVDR) requirements. The updated system now includes new, complementary Applied Biosystems Diomni Software ecosystem to empower clinical labs and test developers to leverage flexible PCR testing onsite. Designed for maximum productivity and fast ramp-up, the QuantStudio 7 Pro Dx Real-Time PCR System enables users to transition from development to validation on a single system.

The expandable, automated platform comes with interchangeable 96-well and 384-well blocks and also includes remote desktop and touchscreen controls, facial authentication, voice command and smart tech support to increase user productivity. Whether performing a routine test or developing a new assay, the integrated, IVDR-compliant Applied Biosystems Diomni Software ecosystem is designed to streamline the entire workflow with a plug-and-play design and simplified set-up to enhance efficiency and minimize user error. The centralized set-up allows connection to multiple real-time PCR instruments and secure data sharing across a user network.

The QuantStudio 7 Pro Dx Real-Time PCR System is available in all regions that recognize CE-IVD certification and is also listed with the U.S. Food and Drug Administration (FDA) as a class II medical device.


ę S&P Capital IQ 2022
All news about THERMO FISHER SCIENTIFIC
09:54aThermo Fisher Scientific Launches TrueMark Infectious Disease Research Panels
AQ
08:16aRBC Initiates Thermo Fisher Scientific at Outperform With $660 Price Target, Cites 'Adv..
MT
12/06Thermo Fisher Scientific Raises Greenhouse Gas Emissions Reduction Target on Path to Ne..
BU
11/29Transcript : Thermo Fisher Scientific Inc. Presents at 5th Annual Evercore IS..
CI
11/29Barclays Cuts Price Target on Thermo Fisher to $570 From $575, Maintains Overweight Rat..
MT
11/21Thermo Fisher Scientific Issues 1.25 Billion Euros of 2026, 2034 Notes
MT
11/21Thermo Fisher Scientific Inc. : Entry into a Material Definitive Agreement, Other Events, ..
AQ
11/21Thermo Fisher Scientific to Present at Evercore ISI HealthCONx Conference
BU
11/18Insider Sell: Thermo Fisher Scientific
MT
11/16Thermo Fisher Scientific : Introduces Rapid Point-of-Care RT-PCR Flu A/Flu B Test
PU
More news
Analyst Recommendations on THERMO FISHER SCIENTIFIC
More recommendations
Financials (USD)
Sales 2022 43 903 M - -
Net income 2022 6 919 M - -
Net Debt 2022 24 827 M - -
P/E ratio 2022 31,9x
Yield 2022 0,21%
Capitalization 220 B 220 B -
EV / Sales 2022 5,58x
EV / Sales 2023 5,45x
Nbr of Employees 130 000
Free-Float 88,9%
Chart THERMO FISHER SCIENTIFIC
Duration : Period :
Thermo Fisher Scientific Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends THERMO FISHER SCIENTIFIC
Short TermMid-TermLong Term
TrendsBullishNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 25
Last Close Price 558,14 $
Average target price 617,84 $
Spread / Average Target 10,7%
EPS Revisions
Managers and Directors
Marc N. Casper Chairman, President & Chief Executive Officer
Stephen Williamson Chief Financial Officer & Senior Vice President
Ryan Snyder Chief Information Officer & Senior Vice President
Alan B. Sachs Chief Medical Officer
Karen E. Nelson Chief Scientific Officer
Sector and Competitors